Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Quoin Pharmaceuticals Ltd ADR (QNRX)

Quoin Pharmaceuticals Ltd ADR (QNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,954
  • Shares Outstanding, K 5,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,690 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.05
  • Most Recent Earnings $-0.47 on 11/07/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year -2.08
  • Growth Rate Est. (year over year) +78.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5698 +5.30%
on 11/15/24
0.9580 -37.37%
on 10/29/24
-0.2080 (-25.74%)
since 10/25/24
3-Month
0.4802 +24.95%
on 10/02/24
1.5700 -61.78%
on 10/16/24
-0.0047 (-0.78%)
since 08/23/24
52-Week
0.4772 +25.73%
on 08/16/24
6.1800 -90.29%
on 03/04/24
-3.9731 (-86.88%)
since 11/24/23

Most Recent Stories

More News
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

QNRX : 0.6000 (+2.56%)
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

QNRX : 0.6000 (+2.56%)
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

QNRX : 0.6000 (+2.56%)
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

QNRX : 0.6000 (+2.56%)
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics

Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics

QNRX : 0.6000 (+2.56%)
ASXC : 0.3479 (+0.64%)
Asensus Shares First Quarter Results and Future Plans

Asensus Shares First Quarter Results and Future Plans

QNRX : 0.6000 (+2.56%)
ASXC : 0.3479 (+0.64%)
Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty...

QNRX : 0.6000 (+2.56%)
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty...

QNRX : 0.6000 (+2.56%)
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada...

QNRX : 0.6000 (+2.56%)
ENDP : 0.2926 (-5.00%)
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

/PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin...

ENDP : 0.2926 (-5.00%)
QNRX : 0.6000 (+2.56%)

Business Summary

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv.

See More

Key Turning Points

3rd Resistance Point 0.6300
2nd Resistance Point 0.6200
1st Resistance Point 0.6100
Last Price 0.6000
1st Support Level 0.5900
2nd Support Level 0.5800
3rd Support Level 0.5700

See More

52-Week High 6.1800
Fibonacci 61.8% 4.0015
Fibonacci 50% 3.3286
Fibonacci 38.2% 2.6557
Last Price 0.6000
52-Week Low 0.4772

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar